Table 1. Patient characteristics,... | American Society of Hematology

Table 1.

Patient characteristics, treatment parameters, whole-body pharmacokinetics, and whole-body and organ dosimetry for patients with NHL receiving ¹³¹I-chimeric 81C6

		Weight, kg	Dosimetric activity, MBq	Therapeutic activity, MBq	Specific activity, MBq kg^-1	Whole-body effective half-life, h	Whole-body residence time, h	Absorbed dose, cGy*
Patient no.	Sex	Weight, kg	Dosimetric activity, MBq	Therapeutic activity, MBq	Specific activity, MBq kg^-1	Whole-body effective half-life, h	Whole-body residence time, h							WB	Thyroid	RM	BS	Blood	Lungs	Kidney	Liver	Spleen	Tumor†
1	M	101	370	1480	18.3	102	147	58	3009	329	508	141	223	213	206	567	1517
2	F	61	370	1480	30.3	109	158	87	2155	505	888	247	297	241	306	650	1258
3	F	79	370	1480	23.4	95	137	76	2375	745	1135	299	264	255	137	450	—
4	F	74	370	1110	20.0	125	180	67	2419	329	566	192	307	429	195	350	811
5	F	59	370	1110	25.1	136	196	89	2056	350	512	240	232	108	133	330	735
6	F	70	370	1110	21.1	90	130	51	1096	370	558	137	312	242	149	474	1198
7	F	86	370	1110	17.2	114	165	54	1416	345	543	177	426	319	158	362	682
8	M	81	370	1110	18.3	121	175	69	2347	232	397	168	220	247	213	370	1060
9	M	97	370	1110	15.3	101	146	53	1820	380	585	143	310	131	96	344	363
Average, cGy/MBq	—	—	—	—	—	—	—	0.04	1.29	0.25	0.51	0.12	0.18	0.15	0.11	0.27	0.60
Minimum, cGy/MBq	—	—	—	—	—	—	—	0.03	0.74	0.16	0.34	0.08	0.12	0.07	0.06	0.22	0.25
Maximum, cGy/MBq	—	—	—	—	—	—	—	0.06	1.63	0.40	0.77	0.16	0.29	0.29	0.17	0.35	0.82

		Weight, kg	Dosimetric activity, MBq	Therapeutic activity, MBq	Specific activity, MBq kg^-1	Whole-body effective half-life, h	Whole-body residence time, h	Absorbed dose, cGy*
Patient no.	Sex	Weight, kg	Dosimetric activity, MBq	Therapeutic activity, MBq	Specific activity, MBq kg^-1	Whole-body effective half-life, h	Whole-body residence time, h							WB	Thyroid	RM	BS	Blood	Lungs	Kidney	Liver	Spleen	Tumor†
1	M	101	370	1480	18.3	102	147	58	3009	329	508	141	223	213	206	567	1517
2	F	61	370	1480	30.3	109	158	87	2155	505	888	247	297	241	306	650	1258
3	F	79	370	1480	23.4	95	137	76	2375	745	1135	299	264	255	137	450	—
4	F	74	370	1110	20.0	125	180	67	2419	329	566	192	307	429	195	350	811
5	F	59	370	1110	25.1	136	196	89	2056	350	512	240	232	108	133	330	735
6	F	70	370	1110	21.1	90	130	51	1096	370	558	137	312	242	149	474	1198
7	F	86	370	1110	17.2	114	165	54	1416	345	543	177	426	319	158	362	682
8	M	81	370	1110	18.3	121	175	69	2347	232	397	168	220	247	213	370	1060
9	M	97	370	1110	15.3	101	146	53	1820	380	585	143	310	131	96	344	363
Average, cGy/MBq	—	—	—	—	—	—	—	0.04	1.29	0.25	0.51	0.12	0.18	0.15	0.11	0.27	0.60
Minimum, cGy/MBq	—	—	—	—	—	—	—	0.03	0.74	0.16	0.34	0.08	0.12	0.07	0.06	0.22	0.25
Maximum, cGy/MBq	—	—	—	—	—	—	—	0.06	1.63	0.40	0.77	0.16	0.29	0.29	0.17	0.35	0.82

RM indicates red marrow; BS, bone surfaces; WB, whole body; —, not applicable.

Absorbed doses were calculated on the basis of total administered activity (DA + TA).

†

Estimated absorbed dose to selected discernible radiographic sites.

View Large

This Feature Is Available To Subscribers Only